A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Bladder Cancer, CIS
Both
Bladder Cancer, CIS
Trial Information
A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Inclusion Criteria:
- Males and females 18 years of age and older
- Diagnosed with NMIBC
- Prescribed intravesical valrubicin to treat NMIBC
- Understood and signed Informed Consent to participate
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Authority:
United States: Institutional Review Board
Study ID:
EN3329-402
NCT ID:
NCT01314664
Start Date:
May 2011
Completion Date:
July 2013
Related Keywords:
- Bladder Cancer
- CIS
- Non-Muscle Invasive Bladder Cancer
- CIS
- BCG Refractory
- Urinary Bladder Neoplasms
Name | Location |
|---|---|
| Vanderbilt University Medical Center | Nashville, Tennessee 37232-2516 |
| Urology Associates of North Texas | Arlington, Texas 76015 |
| Urology Clinics of North Texas | Dallas, Texas 75231 |
| BCG Oncology | Phoenix, Arizona 85032 |
| Urologic Consultants of SE PA | Bala Cynwyd, Pennsylvania 19004 |
| Delaware Valley Urology | Sewell, New Jersey 08080 |
| Urology Research Network | Hialeah, Florida 33149 |
| Advanced Urology Association of Florida | Vero Beach, Florida 32960 |
| Kansas City Urology Care | Overland Park, Kansas 66211 |
| Long Island Urological Associates | Bethpage, New York 11714 |
